All times are listed in CEST (Central European Summer Time)
- Elizabeth Smyth (Cambridge, United Kingdom)
LBA56 - Perioperative or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Results of the NEONAX trial, a randomized phase II AIO study
- Thomas Seufferlein (Ulm, Germany)
Abstract
Background
Data on perioperative chemotherapy (CTX) in resectable pancreatic cancer (rPDAC) are limited. The NEONAX trial examined perioperative or adjuvant CTX with gemcitabine plus nab-paclitaxel in rPDAC (NCCN criteria).
Methods
This is a prospective, randomized phase II study against a fixed survival probability. 127 patients with rPDAC were randomized 1:1 to perioperative (2 pre- and 4 postoperative cycles, arm A, A) or adjuvant (6 cycles, arm B, B) gemcitabine/nab-paclitaxel by 22 German centers from 7/2015 to 10/2019. Primary objective was an improvement of disease free survival (DFS-R) 18mo after randomization from historical 38% to 55% in the mITT population comprising patients who fulfilled the inclusion criteria (ITT, n=59 both arms), were R0/R1 resected and started neoadjuvant (A) or adjuvant CTX (B).
Results
ORR in A was 28.9%, PD rate (RECIST 1.1) during neoadjuvant CTX was 6.7%. Resection rate (RR) was 69.5% in A and 78.0% in B, R0-RR was 87.8% in A and 67.4% in B. In the ITT population (ITT-P) DFS-R at 18mo was 28.7% in A and 19.3% in B, mDFS was 11.4mo in A and 5.9mo in B. Not all patients qualified for the mITT analysis: In A, 66.1% of the ITT-P started neoadjuvant CTX and were R0/R1 resected (mITT). In B only 42.4% of the ITT-P underwent R0/R1 resection and started adjuvant CTX (mITT, see the table). DFS-R at 18mo in mITT (primary endpoint), was 32.2% in A and 41.4% in B not reaching 55% in both arms, the mDFS was 14.1mo and 17.0mo in A and B, respectively.
ITT mITT A (n=59) B (n=59) A (n=39) B (n=25) 28.7 19.3 32.2 41.4 11.4 5.9 14.1 17.0 69.5 78.0 100 100 87.8 67.4 92.3 76.0 30.5 22.0 0 0 PD 6.7 1.7 Intraop. Irresect. 5.1 16.9 Withdrawal of IC (W-IC) 10.1 3.4 Toxicity 8.5 - 91.5 - 100 - 50.8 42.4 76.9 100 15.3 32.2 23.1 0 Early relapse 6.7 16.9 Delayed recovery 3.4 3.4 Death 1.7 5.1 W-IC 0 3.4 Toxicity 3.4 0 Lost to follow-up 0 3.4
Conclusions
Perioperative CTX did not reach a DFS-R at 18mo of 55% in the mITT population. Neoadjuvant CTX showed high R0-RR and long DFS in the ITT-P and could be applied to more patients than adjuvant CTX. Neoadjuvant CTX is proposed to be a new standard for trials also in rPDAC.
Clinical trial identification
AIO-PAK-0313 (NEONAX) EudraCT 2013-005559-34; NCT02047513.
Legal entity responsible for the study
AIO-Studien-gGmbH, Berlin, Germany.
Funding
Bristol Myers Squibb GmbH & Co. KGaA.
Disclosure
T. Seufferlein: Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Advisory Board: Celgene; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Servier; Financial Interests, Personal, Advisory Board: Lilly; Financial Interests, Personal, Advisory Board: Merck Serono; Financial Interests, Personal, Advisory Board: Sanofi-Aventis; Financial Interests, Personal, Advisory Board: Celgene; Financial Interests, Personal, Advisory Board: Bayer; Financial Interests, Personal, Invited Speaker: Amgen; Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Personal, Invited Speaker: Celgene; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Servier; Financial Interests, Personal, Invited Speaker: Merck Serono; Financial Interests, Personal, Invited Speaker: Sanofi-Aventis; Financial Interests, Personal, Research Grant: Celgene; Financial Interests, Personal, Research Grant: Sanofi-Aventis. H. Algül: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Institutional, Research Grant: Chugai; Financial Interests, Personal, Invited Speaker: MSD. V. Kunzmann: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Institutional, Research Grant: BMS. A. Tannapfel: Financial Interests, Personal, Advisory Board: Falk Foundation; Financial Interests, Personal, Advisory Board: Merck; Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: BMS. A. Reinacher-Schick: Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Advisory Board: Merck Serono; Financial Interests, Personal, Advisory Board: Celgene; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Pierre Fabre; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Servier; Financial Interests, Personal, Invited Speaker: Amgen; Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Personal, Invited Speaker: Celgene; Financial Interests, Personal, Invited Speaker: Lilly; Financial Interests, Personal, Invited Speaker: Merck Serono; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Sanofi-Aventis; Financial Interests, Personal, Invited Speaker: Servier; Financial Interests, Institutional, Research Grant: Roche; Financial Interests, Institutional, Research Grant: Ipsen; Financial Interests, Institutional, Research Grant: Amgen; Financial Interests, Institutional, Research Grant: AstraZeneca; Financial Interests, Institutional, Research Grant: Ipsen; Financial Interests, Institutional, Research Grant: Lilly; Financial Interests, Institutional, Research Grant: Servier; Financial Interests, Institutional, Research Grant: RafaelPharmaceutics. T.J. Ettrich: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Bayer; Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Advisory Board: Merck; Financial Interests, Personal, Advisory Board: Ipsen; Financial Interests, Personal, Invited Speaker: Ipsen; Financial Interests, Personal, Advisory Board: Sanofi Aventis; Financial Interests, Personal, Invited Speaker: Eisai; Financial Interests, Personal, Advisory Board: Pierre-Fabre Pharma; Financial Interests, Personal, Advisory Board: Incyte; Financial Interests, Personal, Advisory Board: Lilly; Financial Interests, Personal, Advisory Board: Bristol Myers Squibb; Financial Interests, Institutional, Research Grant: Servier; Financial Interests, Institutional, Research Grant: Sanofi Aventis; Financial Interests, Institutional, Research Grant: Celgene. All other authors have declared no conflicts of interest.
LBA57 - Unicancer PRODIGE 24/CCTG PA6 trial: Updated results of a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas (PDAC)
- Thierry Conroy (Vandoeuvre-lès-Nancy, CEDEX, France)
Abstract
Background
mFFX combination was shown to be superior to Gem alone in adjuvant setting after resection of PDAC for DFS and OS, after a median follow-up (fu) of 36 months (mo) but data were immature, 61% of pts being alive (Conroy T et al., NEJM 2018). Thus, prognostic factors (PrF) for OS were not determined.
Methods
Pts aged 18-79 years (yr) with histologically proven PDAC, WHO PS ≤1, no cardiac ischemia were eligible. Randomization was stratified by center, pN, R margin status and post-operative CA 19-9 level (≤90 vs >90 U/mL). Pts received mFOLFIRINOX every 14 days for 12 cycles or Gem 1000 mg/m2 on days 1, 8, and 15 for six 28-day cycles. Primary endpoint was DFS. Secondary endpoints were OS, metastasis-free survival (MFS), specific survival (SS) and safety. 490 pts (for 342 events) were needed to detect a 10% difference in 3-yr DFS with 80% power (log-rank test with 5% 2-sided α). HR and 95% CI were estimated by a stratified Cox proportional hazard model. Here, we present updated 5-yr outcomes and PrF for OS in the intent-to-treat population.
Results
493 patients had been included and followed, including those alive ≥ 5 yr. With a median fu of 69.7 mo (95% CI: 67.0-73.9), 367 DFS events were observed and the 5-yr DFS rate was 26.1% (95% CI: 20.5-32.1) with mFFX vs 19.0% (95% CI: 14.3-24.3) with Gem, stratified HR=0.66 (95% CI: 0.54-0.82), p=0.0001. The median OS was 53.5 mo (95% CI: 43.5-58.4) in mFFX arm vs 35.5 mo (95% CI: 30.1-40.3) in Gem arm, stratified HR=0.68 (95% CI: 0.54-0.85), p=0.0009. The 5-yr OS rate is 43.2% (95% CI: 36.5-49.7) in mFFX arm vs 31.4% (95% CI 25.5-37.5) in Gem arm. MFS was 29.4 mo (95% CI: 21.4-40.1) in mFFX arm vs 17.7 (95% CI: 14.0-21.2) in Gem arm, stratified HR=0.64, (95% CI: 0.52-0.80), p=0.0001. Median SS was 54.7 mo [45.8-68.4] in mFFX arm vs 36.3 mo [30.5-43.9] in Gem arm, stratified HR=0.65, (95% CI: 0.51-0.82), p=0.0003. Treatment arm, center volume of inclusions, tumor grade, tumor staging, and age were significant PrF for OS in multivariate analysis.
Conclusions
With ≥5 yr fu, updated results of PRODIGE 24/CCTG PA6 trial confirm that adjuvant FFX yields significantly longer DFS, OS, MFS and SS compared to Gem.
Clinical trial identification
EudraCT 2011-002026-52; NCT01526135.
Legal entity responsible for the study
Unicancer.
Funding
Unicancer; INCA; Ligue Nationale Contre le Cancer.
Disclosure
P. Hammel: Financial Interests, Institutional, Other, Financial support for study outside the submitted work: Astrazeneca; Financial Interests, Personal, Other, Personal Fees outside the submitted work: BMS; Financial Interests, Institutional, Other, Financial support for study outside the submitted work: Erytech; Financial Interests, Personal, Other, Personal Fees outside the submitted work: Servier; Financial Interests, Personal, Other, Personal Fees outside the submitted work: Mylan; Financial Interests, Institutional, Other, Financial support for study outside the submitted work: Halozyme. A. Turpin: Financial Interests, Personal, Expert Testimony: Amgen; Financial Interests, Personal, Expert Testimony: Merck-Serono; Financial Interests, Personal, Expert Testimony: Mylan; Financial Interests, Personal, Advisory Board: Servier; Financial Interests, Personal, Advisory Board: AstraZeneca. A. Wei: Financial Interests, Personal, Other, Consulting outside of the submitted work: AstraZeneca; Financial Interests, Personal, Other, Consulting outside of the submitted work: Histosonics; Financial Interests, Personal, Other, Travelling costs outside of the submitted work: Intuitive Surgical. A. Lopez: Financial Interests, Institutional, Research Grant: Roche; Financial Interests, Personal, Other, Lecture fees: Vifor pharma; Financial Interests, Personal, Other, Lecture fees: Bayer; Financial Interests, Personal, Other, Lecture fees: Merck; Financial Interests, Personal, Other, Lecture fees: Sanofi; Financial Interests, Personal, Other, Travel accomodation expenses (not for this work): AbbVie; Financial Interests, Personal, Other, Travel accomodation expenses (not for this work): Amgen; Financial Interests, Personal, Other, Travel accomodation expenses (not for this work): MSD; Financial Interests, Personal, Other, Travel accomodation expenses (not for this work): Vifor-Pharma; Financial Interests, Personal, Other, Travel accomodation expenses (not for this work): Mundi Pharma; Financial Interests, Personal, Other, Travel accomodation expenses (not for this work): Ipsen; Financial Interests, Personal, Other, Travel accomodation expenses (not for this work): Novartis; Financial Interests, Personal, Other, Consultant: Amgen. E. Francois: Financial Interests, Personal, Advisory Board: Pierre Fabre; Financial Interests, Personal, Sponsor/Funding: Amgen; Financial Interests, Personal, Advisory Role: MSD. P. Artru: Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Advisory Board: Servier; Financial Interests, Personal, Advisory Board: Pierre Fabre; Financial Interests, Personal, Advisory Board: Merck; Financial Interests, Personal, Advisory Board: Bayer. T. Lecomte: Financial Interests, Institutional, Principal Investigator: Ipsen; Financial Interests, Institutional, Principal Investigator: Astellas; Financial Interests, Institutional, Principal Investigator: ERYTHEC Pharma; Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Advisory Role: Ipsen. E. Assenat: Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: AAA; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Ipsen; Financial Interests, Personal, Advisory Board: Bayer. O. Bouche: Financial Interests, Personal, Other, Honoraria (self): Merck KGaA; Financial Interests, Personal, Other, Honoraria (self): Roche; Financial Interests, Personal, Other, Honoraria (self): Bayer; Financial Interests, Personal, Other, Honoraria (self): AstraZeneca; Financial Interests, Personal, Other, Honoraria (self): Grunenthal; Financial Interests, Personal, Other, Honoraria (self): MSD; Financial Interests, Personal, Other, Honoraria (self): Amgen; Financial Interests, Personal, Other, Honoraria (self): Servier; Financial Interests, Personal, Other, Honoraria (self): Pierre Fabre; Financial Interests, Personal, Advisory Role: Merck KGaA; Financial Interests, Personal, Advisory Role: Roche; Financial Interests, Personal, Advisory Role: Bayer; Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Advisory Role: Grunenthal; Financial Interests, Personal, Advisory Role: MSD; Financial Interests, Personal, Other, Speaker Bureau/Expert Testimony: Amgen; Financial Interests, Personal, Other, Speaker Bureau/Expert Testimony: Servier; Financial Interests, Personal, Other, Speaker Bureau/Expert Testimony: Pierre Fabre; Financial Interests, Personal, Other, Travel/Accommodation/Expenses: Roche; Financial Interests, Personal, Other, Travel/Accommodation/Expenses: Servier. A. Lambert: Financial Interests, Personal, Advisory Board: Janssen; Financial Interests, Personal, Advisory Board: AAA; Financial Interests, Personal, Advisory Board: Servier; Financial Interests, Personal, Advisory Board: Merck; Financial Interests, Personal, Advisory Board: Bayer; Financial Interests, Personal, Advisory Board: Ipsen; Financial Interests, Personal, Advisory Board: Tesaro; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Viatris; Financial Interests, Personal, Advisory Board: Roche; Non-Financial Interests, Personal, Principal Investigator: Roche; Non-Financial Interests, Personal, Principal Investigator: Innovent Biologics; Non-Financial Interests, Personal, Principal Investigator: Keocyt; Non-Financial Interests, Personal, Principal Investigator: MSD. P. Rat: Financial Interests, Personal, Royalties: HIPEC device – Landanger society, Chaumont, France; Non-Financial Interests, Personal, Member: AFC - Société de Chirurgie de Lyon. J. Bachet: Financial Interests, Personal, Invited Speaker: Amgen; Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Invited Speaker: Bayer; Financial Interests, Personal, Invited Speaker: Merck Serono; Financial Interests, Personal, Invited Speaker: Pierre Fabre; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Sanofi; Financial Interests, Personal, Invited Speaker: Servier; Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Bayer; Financial Interests, Personal, Advisory Board: Merck Serono; Financial Interests, Personal, Advisory Board: Pierre Fabre; Financial Interests, Personal, Advisory Board: Servier. All other authors have declared no conflicts of interest.
Invited Discussant LBA56 and LBA57
- Andrew H. Ko (San Francisco, United States of America)
Q&A and live discussion
- Elizabeth Smyth (Cambridge, United Kingdom)
1376O - The effect of hyperthermic intraperitoneal chemotherapy (HIPEC) upon cytoreductive surgery (CRS) in gastric cancer (GC) with synchronous peritoneal metastasis (PM): A randomized multicentre phase III trial (GASTRIPEC-I-trial)
- Beate Rau (Berlin, Germany)
Abstract
Background
In patients (pts) with PM from GC, palliative chemotherapy (CTx) is the treatment of choice. CRS and HIPEC is still matter of debate, as the evidence is controversial. We conducted a randomized controlled multicentre trial to explore the impact of HIPEC after CRS on overall survival (OS). (Funding German Cancer Aid; ClinicalTrials.gov, number NCT02158988).
Methods
Pts with GC and histologically proven PM were randomized to arm CRS alone (with curative intent) (CRS-A) or arm CRS and HIPEC (CRS+H) with pre- and post-operative (op) CTx. CTx was defined as EOX; in case of HER-2 positivity it contained Cisplatin, Capecitabine and Trastuzumab. The HIPEC treatment consisted of Mitomycin C 15 mg/m2 and Cisplatin 75 mg/m2, in 5 litres of saline (60 min, 42 °C). Randomisation was stratified by centre, PCI, and HER2 status. The primary endpoint (EP) was OS, secondary EP progression and other distant metastasis free survival (PFS and MFS). Power analysis computed 180 pts. Analyses followed the intention to treat and time-to-event data by Fleming-Harrington test.
Results
Between 03/2014 and 06/2018 105 pts were randomized (52 pts to CRS+H and 53 pts to CRS-A) and recruitment was stopped due to slow recruitment. In total, 55 pts stopped treatment before CRS (disease progression or death). The median OS for both groups was 14.9 months (CRS-A 14.9 months (95% CI: 7.0-19.4) vs (CRS+H 14.9 months 95% CI: 8.7-17.7; p=0.1647). PFS was significantly improved from 3.5 months (95% CI 3.0-7.0) in the CRS-A group to 7.1 months (95% CI 3.7-10.5; p=0.0472) in the CRS+H group. The CRS+H group showed a better MFS 10.2 months (95% COI: 7.7-14.7) compared to 9.2 months (95% COI: 6.8-11.5; p=0.0286). Pts with grade
Conclusions
The study showed no difference in OS in pts treated with CRS ± HIPEC. However, the PFS and MFS were significantly better in the CRS+H group. Therefore, further investigations seem worthwhile. Additional HIPEC did not compromise patient’s safety.
Clinical trial identification
NCT02158988; EudraCT 2006-006088-22.
Legal entity responsible for the study
Charité - University of Berlin.
Funding
German Cancer Aid.
Disclosure
B. Rau: Other, Institutional, Principal Investigator: German Cancer Aid. H. Lang: Financial Interests, Personal, Advisory Board: Humedics. D. Reim: Other, Personal and Institutional, Research Grant, Clinical Trial: DFK; Other, Personal and Institutional, Principal Investigator, Clinical Trial: TAKEDA. P.C. Thuss-Patience: Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Astra-Zeneca; Financial Interests, Personal, Advisory Board: Lilly; Financial Interests, Personal, Advisory Board: Servier. All other authors have declared no conflicts of interest.
Invited Discussant 1376O
- Brian Badgwell (Houston, United States of America)
Q&A and live discussion
- Elizabeth Smyth (Cambridge, United Kingdom)
1372O - CLDN 18.2-targeted CAR-T cell therapy in patients with cancers of the digestive system
- Changsong Qi (Beijing, China)
Abstract
Background
Efficacy of chimeric antigen receptor-engineered T (CAR-T) cell therapy against solid tumors is still limited. CLDN18.2 is a promising target highly expressed in various cancer types of the digestive system. CT041, an anti-CLDN18.2 CAR-T cell therapy, showed promising anti-tumor activities in preclinical studies and an investigator-initiated study (CT041-CG4003 NCT03159819). This newly initiated phase I study was conducted to assess the safety and efficacy of CT041 produced with a modified manufacturing process.
Methods
Patients with CLDN18.2+ cancers of digestive system received CT041 at doses of 2.5×108, 3.75×108 or 5×108 CAR-T cells after preconditioning chemotherapy. The objective was to assess the safety, efficacy and cytokinetic profile of CT041.
Results
As of April 8, 2021, a total of 37 patients with cancer of digestive system, including 28 with gastric cancer (GC), 5 with pancreatic ductal adenocarcinoma (PDAC) and 4 with other cancer types, received CT041 infusion and completed at least 12 weeks of follow-up after the first infusion for the last subject. Cell doses of 2.5×108, 3.75×108 and 5×108 were administrated in 28, 6 and 3 patients, respectively. With a median follow-up of 7.6 months (95%CI 5.6, 8.6), all patients experienced ≥G3 hematologic toxicity while no DLT was observed. Immune effector cell-associated neurotoxicity syndrome, treatment-related death and ≥G3 cytokine release syndrome was not observed. The overall ORR for all patients and patients with GC were 48.6% (95%CI, 31.9%, 65.6%) and 57.1% (95%CI, 37.2, 75.5) respectively. At the dose level of 2.5×108, 18 patients with GC who have failed at least 2 prior lines of therapy including 44% (8/18) exposure to anti-PD-(L)1 antibody, the overall ORR, median PFS and OS was 61.1% (11/18), 5.4 months (95%CI, 2.6, NE) and 9.5 months (95%CI, 5.2, NE) respectively.
Conclusions
CT041 showed acceptable safety profile and promising anti-tumor activities in patients with refractory CLDN18.2+ cancers of digestive system. In patients with GC who have failed at least 2 prior lines of therapy, CT041 displayed a significantly improved efficacy compared to historical data.
Clinical trial identification
NCT03874897, first posted：March 14, 2019.
Legal entity responsible for the study
Peking University Cancer Hospital & Institute.
Funding
CARsgen Therapeutics Co., Ltd.
Disclosure
C. Qi: Other, Personal and Institutional, Other, sub-investigator: CARsgen Therapeutics. Y. Qin: Other, Personal and Institutional, Principal Investigator: CARsgen Therapeutics. D. Liu: Other, Personal and Institutional, Other, sub-investigator: CARsgen Therapeutics. J. Gong: Other, Personal and Institutional, Other, sub-investigator: CARsgen Therapeutics. X. Peng: Financial Interests, Personal, Full or part-time Employment: CARsgen Therapeutics. H. Wang: Financial Interests, Personal, Full or part-time Employment: CARsgen Therapeutics. C. He: Financial Interests, Personal, Full or part-time Employment: CARsgen Therapeutics. J. Xiao: Financial Interests, Personal, Full or part-time Employment: CARsgen Therapeutics. Z. Li: Financial Interests, Personal, Full or part-time Employment: CARsgen Therapeutics. L. Shen: Other, Personal and Institutional, Principal Investigator: CARsgen Therapeutics. All other authors have declared no conflicts of interest.
Invited Discussant 1372O
- Kohei Shitara (Kashiwa, Chiba, Japan)
Q&A and live discussion
- Elizabeth Smyth (Cambridge, United Kingdom)